Agios Pharmaceuticals is a biopharmaceutical company focused on rare genetic and hematologic diseases driven by cellular metabolism. Its portfolio is best known for therapies addressing pyruvate kinase deficiency and related red-blood-cell disorders. The company targets patients and specialists in rare blood diseases rather than broad primary-care markets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 12.5 | — | -112 | — |
| Q3 2025 | 12.9 | — | -103.4 | — |
| Q4 2025 | 20 | — | -108 | — |
| Q1 2026 | 20.8 | — | -99.1 | — |
| Q2 2026 | 44.7 | 259.3% | -100.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Karooooo Ltd. (KARO), Recursion Pharmaceuticals, Inc. (RXRX), Novavax, Inc. (NVAX), Cimpress plc (CMPR), LeMaitre Vascular, Inc. (LMAT), Amplitude, Inc. (AMPL)